<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="be caused by the high dose of steroid treatment using" exact="methylprednisolone" post="[43]. In another study, Nguyen et al. explored changes"/>
 <result pre="47 lipid species/classes such as arachidonic acid, docosahexaenoic acid, and" exact="eicosapentaenoic acid" post="were consistently upregulated after infection [45]. These data highlight"/>
 <result pre="clinical trial, Makris et al. studied the impact of using" exact="pravastatin" post="on reducing the frequency of ventilator-associated pneumonia. Moreover, they"/>
 <result pre="studies looked at the effect of a combination therapy using" exact="atorvastatin" post="(40 mg/day) and irbesartan (150 mg/day). Statinâ€™s beneficial impact"/>
 <result pre="effect of a combination therapy using atorvastatin (40 mg/day) and" exact="irbesartan" post="(150 mg/day). Statinâ€™s beneficial impact on viral infection could"/>
 <result pre="drug library and showed that AM580, a retinoid acid receptor" exact="alpha" post="(RAR-a) agonist could interrupt the life cycle of MERS-CoV"/>
 <result pre="of COVID-19 infection [76]. On this basis, the FDA-approved immunomodulator" exact="FTY720" post="(Fingolimod), one of the best characterized â€œsphingomimeticâ€� drugs [75],"/>
 <result pre="associated with slow multiple sclerosis progression and good response to" exact="fingolimod" post="treatment [81]. Recently, more specific functionally related compounds have"/>
 <result pre="short term mortality after pneumonia episode: Cohort studyBMJ2011342d164210.1136/bmj.d164221471172 58.MakrisD.ManoulakasE.KomnosA.PapakrivouE.TzovarasN.HovasA.ZintzarasE.ZakynthinosE.Effect of" exact="pravastatin" post="on the frequency of ventilator-associated pneumonia and on intensive"/>
 <result pre="diseaseNat. Rev. Mol. Cell Biol.20181917519110.1038/nrm.2017.10729165427 75.HuwilerA.Zangemeister-WittkeU.The sphingosine 1-phosphate receptor modulator" exact="fingolimod" post="as a therapeutic agent: Recent findings and new perspectivesPharmacol."/>
 <result pre="with multiple sclerosisNeurology20158487287910.1212/WNL.000000000000130225636714 81.Al-TemaimiR.CherianP.Abu-FarhaM.AlroughaniR.Angiopoietin-like proteins in multiple sclerosisJ. Neuroimmunol.2019330313410.1016/j.jneuroim.2019.02.00630784773 82.ChewW.S.WangW.HerrD.R.To" exact="fingolimod" post="and beyond: The rich pipeline of drug candidates that"/>
</results>
